Vikram Prakash
Neurology with Special Qualifications in Child Neurology · Orlando, FLNPI 1972815983
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (52.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Mirum Pharmaceuticals, Inc. accounts for 93.4% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $14,307, more than ten times the $31 reported in 2020.
Across 37 payments — averaging $407.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mirum Pharmaceuticals, Inc.$14K
- Acadia Pharmaceuticals Inc$215
- UCB, Inc.$173
- Jazz Pharmaceuticals Inc.$159
- Cadwell Industries, Inc$156
- Neurelis, Inc.$112
- plus $178 from 8 others
Across 45 payments — averaging $2614.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$69K
- Immedica Pharma US, Inc.$24K
- UCB SA$21K
- Mirum Pharmaceuticals, Inc.$3K
What the payments were for
- Consulting fees$5,40036%
- Travel & lodging$7,97653%
- Food & beverage$1,0757%
- Education$6144%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mirum Pharmaceuticals, Inc. | 7 | $14,070 |
| Acadia Pharmaceuticals Inc | 7 | $215 |
| UCB, Inc. | 5 | $173 |
| Jazz Pharmaceuticals Inc. | 3 | $159 |
| Cadwell Industries, Inc | 1 | $156 |
| Neurelis, Inc. | 5 | $112 |
| Biogen | 1 | $31 |
| AbbVie | 1 | $31 |
| Catalyst Pharmaceuticals, Inc. | 1 | $24 |
| Nobelpharma America, LLC | 1 | $23 |
| AstraZeneca | 1 | $23 |
| Travere Therapeutics, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Aucta Pharmaceuticals, Inc. | 2 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (820) Cholbam$13,928
- CTEXLI$13,928
- DAYBUE$125
- Epidiolex$109
How this compares
$15,065 in reported general payments places this provider in the 75th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxcarbazepine | 11 | $864 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Orlando
- Omer Abdul HamidOrlando$283K
- Ngoc Minh leOrlando$19K
- Ki-Hyeong LeeOrlando$15K
- Sheila Ramos MartinezOrlando$8K
- Anthony GiordanoOrlando$7K
- Murtuza KothawalaOrlando$5K
- Carl BarrOrlando$5K
- Dina DahanOrlando$5K
- Antonio Vazquez-DiazOrlando$5K
- Paul WinnerWest Palm Beach$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.